Resverlogix Corp. (TSE:RVX – Get Free Report) shares reached a new 52-week low during mid-day trading on Monday . The stock traded as low as C$0.06 and last traded at C$0.06, with a volume of 7500 shares. The stock had previously closed at C$0.06.
Resverlogix Price Performance
The stock has a market capitalization of C$14.97 million, a price-to-earnings ratio of -1.10 and a beta of 0.78. The business’s 50-day simple moving average is C$0.06 and its two-hundred day simple moving average is C$0.07.
Resverlogix Company Profile
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases.
Featured Articles
- Five stocks we like better than Resverlogix
- Do ETFs Pay Dividends? What You Need to Know
- United Airlines Soars on Earnings Beat
- How to Choose Top Rated Stocks
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
